Now that the biotechnology sector is bouncing back after bottoming earlier this year, some investors may feel like they missed out. Not to worry, you didn’t, and there are still many undiscovered companies that could be set to make a name for themselves.
The misconceptions previously plaguing biotech stocks are no longer as big a threat as originally thought. The government no longer puts the sector companies as a whole in their cross hairs – for now. This positive environment could help biotech firms conduct their plans for the remainder of the year and into 2019.
Some companies to look into include Cronos Group, Inc. (CRON) Aurora Cannabis (ACBFF), Rubius Therapeutics, Inc. (RUBY) and CEL-SCI Corporation (CVM).
Cronos Group, Inc.
Market Cap: $2.21B Share Price: $12.51
Canadian cannabis company Cronos Group Inc. is partnering with Aleafia Health Inc. in a medical marijuana study aiming to improve the management and treatment of insomnia and daytime sleepiness. The study will be partly funded by Peace Naturals Project Inc., a licensed producer of medical marijuana that is wholly owned by Cronos. Aleafia is a medical marijuana company that is focused on patient care from “seed” to “sale” with more than 50,000 patients. Canada is preparing to fully legalize cannabis for adult recreational and medical use on Oct. 17.
Market Cap: $8.82B Share Price: $9.22
Aurora Cannabis Inc. announced that it has scheduled its conference call to discuss the results for its fourth quarter ended June 30, 2018. The call will be hosted on Tuesday, September 25 th, 2018 at 11:00 a.m. Eastern Time by Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley , Chief Corporate Officer followed by a question and answer period.
Rubius Therapeutics, Inc.
Market Cap: $1.80B Share Price: $22.82
Rubius Therapeutics, Inc. RUBY, +1.35% a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Tuesday, October 2, 2018, at 9:00 a.m. ET.
A live audio webcast will be available within the Investor and News section of the Rubius Therapeutics’ website. An archived replay will be accessible for 90 days following the event.
Acadia Pharmaceuticals, Inc.
Market Cap: $2.52B Share Price: $20.17
The Food and Drug Administration assigned ACADIA Pharmaceuticals Inc.’s Nuplazid a positive safety profile Thursday, sending shares soaring 27 percent.